Immune & Autoimmune Boost Stack
Reboot the immune code — boosting T-cell function while modulating autoimmune flares.
Stack Overview
About This Stack
Thymosin α-1 (Ta1), LL-37 (antimicrobial peptide), and Humanin form this immune modulation combination. Thymosin α-1 boosts T-cell maturation and restores immune balance — used to enhance immune surveillance in chronic infections and cancer. LL-37 (cathelicidin) fights microbes and may quell autoimmune skin flares. Humanin reduces autoimmune-related inflammation and protects cells under stress. Emer's RECODEX uses Ta1 in RE:VIVE™ phase to "reboot immune code" safely. Humanin is added for older patients with immune senescence, potentially preventing autoimmune flare by reducing inflammatory signaling.
Composition
What's In This Stack
Boosts T-cell maturation and restores immune balance. Used to enhance immune surveillance in chronic infections and cancer. Given to cancer patients as adjunct (improves response to chemo by immune enhancement). Ta1 injections improve outcomes and lower infection risk during chemo.
Dose: 1.6 mg SC 2–3×/week
Route: Subcutaneous
Cathelicidin — fights microbes and may quell autoimmune skin flares. Has broad antimicrobial, antiviral, and immunomodulatory effects. Particularly useful for patients with HBV/HCV or recurrent infections alongside autoimmune conditions.
Dose: As prescribed per protocol; typically compounded for SC or topical use
Route: Subcutaneous or topical
Mitochondrial-derived peptide — reduces autoimmune-related inflammation and protects cells under stress. Broad cytoprotective and anti-aging properties. Used for older patients with immune senescence; potentially prevents autoimmune flare by reducing inflammatory signaling and reducing oxidative damage.
Dose: 10 mg SC weekly
Route: Subcutaneous
Protocol
Treatment Protocol
Thymosin α-1: 1.6 mg SC 2–3×/week for 6–12 week cycles, or longer in cancer adjunct use. LL-37 as compounded per phenotype. Humanin 10 mg SC weekly ongoing. Used in RE:VIVE™ phase of RECODEX or as standalone immune modulation cycle. Lab monitoring: immune panel (T-cell counts, CBC, inflammatory markers) before and after series.
Patient Fit
Ideal For
- Patients with autoimmune conditions (lupus, psoriasis)
- Patients with frequent infections or immunosuppression
- Cancer patients as adjunctive oncology support (with oncologist consent)
- Patients with HBV/HCV or chronic viral conditions
- Older patients with immune senescence or accelerated immune aging
Results
Clinical Outcomes
Thymosin α-1 has clinical evidence in cancer adjunctive therapy — enhancing tumor-fighting immunity and reducing chemo-induced immune suppression. LL-37 provides antimicrobial coverage and may reduce autoimmune skin flares. Humanin is generally very well tolerated and shows anti-inflammatory and neuroprotective effects in animal models. Together the stack aims to "reboot immune code" — restoring normal immune surveillance while dampening inappropriate inflammatory responses.
Begin Your RECODEX™ Protocol
All peptide stacks are physician-supervised and custom-tailored.
Request Consultation
